Boehringer's operating income edges up on Jardiance, animal health
Reuters
Published Apr 05, 2022 04:08AM ET
Updated Apr 05, 2022 05:11AM ET
FRANKFURT (Reuters) - Germany's unlisted Boehringer Ingelheim said operating income rose 1.8% in 2021, driven by more prescriptions of diabetes drug Jardiance and demand for its veterinary drugs as people purchased pets during the pandemic.
Family-owned Boehringer said in a statement on Tuesday that full-year operating income came in at 4.7 billion euros ($5.16 billion), up from 4.6 billion a year earlier.
The Jardiance group of products, managed in a partnership with Eli Lilly (NYSE:LLY), had 3.9 billion euros in sales, up 25.5%. The diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and also for the treatment of heart failure.
Sales of pulmonary fibrosis drug Ofev rose 21.2% to 2.5 billion euros.
Growth in animal health products, such as antiparasitics for dogs and cats, was fuelled by more people acquiring a new pet during the pandemic, but Boehringer said it expects to "see a normalization of the market growth trend" in 2022.
For 2022, Boehringer predicted slightly lower group operating income on higher spending on research and development, while revenues are expected to increase slightly.
($1 = 0.9104 euros)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.